Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...

(Reuters) -Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease, after it succeeded in three out ...

Axsome Therapeutics (NASDAQ:AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05, or dextromethorphan-bupropion, in the treatment of agitation in ...